145 related articles for article (PubMed ID: 35061384)
1. Development of Novel Dihydrofuro[3,4-
Kang D; Sun Y; Feng D; Gao S; Wang Z; Jing L; Zhang T; Jiang X; Lin H; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2022 Feb; 65(3):2458-2470. PubMed ID: 35061384
[TBL] [Abstract][Full Text] [Related]
2. Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
Kang D; Zhang H; Wang Z; Zhao T; Ginex T; Luque FJ; Yang Y; Wu G; Feng D; Wei F; Zhang J; De Clercq E; Pannecouque C; Chen CH; Lee KH; Murugan NA; Steitz TA; Zhan P; Liu X
J Med Chem; 2019 Feb; 62(3):1484-1501. PubMed ID: 30624934
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
[TBL] [Abstract][Full Text] [Related]
5. 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
Kang D; Ruiz FX; Sun Y; Feng D; Jing L; Wang Z; Zhang T; Gao S; Sun L; De Clercq E; Pannecouque C; Arnold E; Zhan P; Liu X
J Med Chem; 2021 Apr; 64(7):4239-4256. PubMed ID: 33734714
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
[TBL] [Abstract][Full Text] [Related]
7. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Dihydrothiopyrano[4,3-
Wang Z; Zalloum WA; Wang W; Jiang X; De Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
J Med Chem; 2021 Sep; 64(18):13658-13675. PubMed ID: 34432448
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Kang D; Fang Z; Huang B; Lu X; Zhang H; Xu H; Huo Z; Zhou Z; Yu Z; Meng Q; Wu G; Ding X; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2017 May; 60(10):4424-4443. PubMed ID: 28481112
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.
Kang D; Feng D; Sun Y; Fang Z; Wei F; De Clercq E; Pannecouque C; Liu X; Zhan P
J Med Chem; 2020 May; 63(9):4837-4848. PubMed ID: 32293182
[TBL] [Abstract][Full Text] [Related]
11. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
[TBL] [Abstract][Full Text] [Related]
12. New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
Nalli M; Armijos Rivera JI; Masci D; Coluccia A; Badia R; Riveira-Muñoz E; Brambilla A; Cinquina E; Turriziani O; Falasca F; Catalano M; Limatola C; Esté JA; Maga G; Silvestri R; Crespan E; La Regina G
Eur J Med Chem; 2020 Dec; 208():112696. PubMed ID: 32883642
[TBL] [Abstract][Full Text] [Related]
13. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
[TBL] [Abstract][Full Text] [Related]
16. Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
Feng D; Lin H; Jiang L; Wang Z; Sun Y; Zhou Z; Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364360
[TBL] [Abstract][Full Text] [Related]
17. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity.
Huang B; Kang D; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
Chem Biol Drug Des; 2021 Jan; 97(1):67-76. PubMed ID: 32725669
[TBL] [Abstract][Full Text] [Related]
19. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
